October 27, 2022
(press release)
–
For patients with insulin-dependent diabetes, maintaining a healthy blood glucose level can be challenging, says GlobalData. The leading data and analytics company notes that automated insulin delivery (AID) systems, or hybrid closed loop systems, have been developed to make maintaining a healthy glucose level easier. This has led to increased awareness among patients with insulin-dependent diabetes. Tina Deng, MSc, Principal Medical Devices Analyst at GlobalData, comments: “AID systems, or hybrid closed loop systems, allow for a complete circle of communication between a continuous glucose monitor (CGM) and insulin pump, which track blood glucose and automatically adjust insulin delivery to help control blood glucose levels. Based on a few large, randomized, controlled outpatient studies for children and adults, recent developments in AID systems have led to improved clinical outcomes, including overall time-in-range improvement by an average of 10%, reduced frequency of diabetic ketoacidosis hospitalizations, and decrease in hypoglycemia and time-below-range.” According to GlobalData’s analysis, the CGM and insulin pumps market is valued at $10.7 billion in 2021. It will reach $20.2 billion in 2030, with a compound annual growth rate (CAGR) of 7.3% from 2021 to 2030. Deng continues: “The market is driven by the increase in the prevalence of people with diabetes and growing awareness among consumers regarding the availability of new technological advancements such as AID in the market. While AID systems are primarily used in type 1 diabetes, patients with type 2 diabetes taking multiple daily injections can also benefit from this technology.” According to GlobalData’s clinical trials database, there have been more than 60 ongoing or planned clinical trials for AID. Most of them focus on the safety and efficacy in different subpopulations, including young children, athletes, and pregnant women. Other trials test innovation in improving pipeline or marketed AID systems, such as better interoperability between different pumps and CGMs, more affordable devices, and easier general usability. Recently, an NIH-funded research team led by Dr. Russell at Massachusetts General Hospital developed an AID system with less user input than existing methods. The researchers tested the device in a randomized trial with more than 300 participants with type 1 diabetes in 16 clinical centers in the US. It was found that this system could safely improve glucose control with much less input from users and their healthcare providers, making day-to-day management of type 1 diabetes easier, leading to better quality of life. Deng concludes: “The more positive clinical outcome is expected to boost the innovation and application of AID, driving the device market to a new level in the future.”
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
